# PV-10 vs Chemotherapy or Oncolytic Viral Therapy for Treatment of Locally Advanced Cutaneous Melanoma

> **NCT02288897** · PHASE3 · TERMINATED · sponsor: **Provectus Biopharmaceuticals, Inc.** · enrollment: 20 (actual)

## Conditions studied

- Cutaneous Melanoma

## Interventions

- **DRUG:** PV-10 (10% rose bengal disodium)
- **DRUG:** Dacarbazine, temozolomide or talimogene laherparepvec

## Key facts

- **NCT ID:** NCT02288897
- **Lead sponsor:** Provectus Biopharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-04
- **Primary completion:** 2019-04
- **Final completion:** 2019-09
- **Target enrollment:** 20 (ACTUAL)
- **Why stopped:** Inadequate rate of enrollment
- **Last updated:** 2022-01-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02288897

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02288897, "PV-10 vs Chemotherapy or Oncolytic Viral Therapy for Treatment of Locally Advanced Cutaneous Melanoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02288897. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*